First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalized patients who are critically ill, according to the first randomized trial of its kind involving 237 adults from 10 hospitals in Wuhan, China.

from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/04/200429134020.htm